Emerging roles of apolipoprotein E4 in cerebral small vessel disease-related cognitive impairment: mechanistic insights and therapeutic perspectives.
- 1Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
- 2Heilongjiang University of Chinese Medicine Affiliated Hospital, Harbin, Heilongjiang, China.
Abstract
Cerebral small vessel disease (CSVD) is a major contributor to cognitive decline and vascular cognitive impairment in the elderly. However, the extent to which apolipoprotein E4 (ApoE4) contributes to sporadic, non-amyloid CSVD remains unclear. Previous literature has often inferred CSVD mechanisms from Alzheimer's disease (AD) research, carrying the risk of overstating disease-specific causal relationships. Therefore, this narrative review re-evaluates the relationship between ApoE4 and CSVD using a CSVD-centric hierarchy of evidence. Population-based imaging and epidemiological data suggest that "APOE" ε4 may alter susceptibility to white matter injury and cognitive impairment; however, the effect sizes are generally small or context-dependent, and associations are influenced by factors such as age, hypertension, diabetes, total vascular risk burden, AD pathology, ancestry, sex, and "APOE" gene dosage. Evidence is stronger for cerebral amyloid angiopathy (CAA)-which involves mechanisms distinct from sporadic arteriolosclerotic CSVD-and thus warrants separate discussion. At the mechanistic level, direct evidence regarding CSVD supports endothelial dysfunction, BBB leakage, neurovascular unit (NVU) instability, and white matter injury as core pathological processes. Among the evidence specific to ApoE4, models involving impaired neurovascular regulation and chronic hypoperfusion are the most compelling; conversely, mechanisms such as the cyclophilin A-MMP-9 pathway, TREM2-ApoE signaling, insulin receptor trafficking, reelin-related synaptic effects, endoplasmic reticulum stress, and autophagy currently rely primarily on AD research or preclinical evidence. Two recently proposed specific hypotheses-the brain-heart-kidney axis hypothesis and the microglial lipid droplet model-offer valuable conceptual frameworks but should be viewed as testable theories rather than established mechanisms. To date, no ApoE4-targeted therapies have been proven effective for CSVD-related cognitive impairment future research should prioritize genotype-stratified longitudinal CSVD cohorts, standardized imaging studies, adjustment for Alzheimer's disease (AD) biomarkers, analysis of interactions between vascular risk factors, studies on human white matter tissue, and the development of ApoE4 disease models that integrate chronic hypoperfusion and vascular comorbidities.
Related
- The Role of Herbal Medicines in Cognitive Impairment: A Narrative Review of Neuroprotective Mechanisms and Therapeutic Perspectives
- Microbial metabolites in chemotherapy-induced cognitive impairment: from mechanistic associations to pharmacological target validation
- Bile Acids and Their Receptors in Respiratory Diseases: Mechanistic and Therapeutic Perspectives
- Extracellular vesicle miRNAs, NOS/NO homeostasis, and NLRP3 inflammasome signaling in schizophrenia-related cognitive impairment: a mechanistic review and testable hypothesis
- Periostin in diabetic kidney disease: mechanistic insights, biomarkers, and therapeutic perspectives
BibTeX
@article{li2026emerging,
title = {{Emerging roles of apolipoprotein E4 in cerebral small vessel disease-related cognitive impairment: mechanistic insights and therapeutic perspectives.}},
author = {Mengru Li and Yu Zhang and Peizhu Lü and Junchen Li and Yu Zhang and Shun Wang and Yan Bai and Yulin Wang},
journal = {Frontiers in human neuroscience},
year = {2026},
month = oct,
doi = {10.3389/fnhum.2026.1957032},
url = {https://europepmc.org/article/MED/42948355},
note = {CC BY},
}
RIS
TY - JOUR
TI - Emerging roles of apolipoprotein E4 in cerebral small vessel disease-related cognitive impairment: mechanistic insights and therapeutic perspectives.
AU - Mengru Li
AU - Yu Zhang
AU - Peizhu Lü
AU - Junchen Li
AU - Yu Zhang
AU - Shun Wang
AU - Yan Bai
AU - Yulin Wang
PY - 2026
DA - 2026/10/13
JO - Frontiers in human neuroscience
DO - 10.3389/fnhum.2026.1957032
UR - https://europepmc.org/article/MED/42948355
AB - Cerebral small vessel disease (CSVD) is a major contributor to cognitive decline and vascular cognitive impairment in the elderly. However, the extent to which apolipoprotein E4 (ApoE4) contributes to sporadic, non-amyloid CSVD remains unclear. Previous literature has often inferred CSVD mechanisms from Alzheimer's disease (AD) research, carrying the risk of overstating disease-specific causal relationships. Therefore, this narrative review re-evaluates the relationship between ApoE4 and CSVD using a CSVD-centric hierarchy of evidence. Population-based imaging and epidemiological data suggest that "APOE" ε4 may alter susceptibility to white matter injury and cognitive impairment; however, the effect sizes are generally small or context-dependent, and associations are influenced by factors such as age, hypertension, diabetes, total vascular risk burden, AD pathology, ancestry, sex, and "APOE" gene dosage. Evidence is stronger for cerebral amyloid angiopathy (CAA)-which involves mechanisms distinct from sporadic arteriolosclerotic CSVD-and thus warrants separate discussion. At the mechanistic level, direct evidence regarding CSVD supports endothelial dysfunction, BBB leakage, neurovascular unit (NVU) instability, and white matter injury as core pathological processes. Among the evidence specific to ApoE4, models involving impaired neurovascular regulation and chronic hypoperfusion are the most compelling; conversely, mechanisms such as the cyclophilin A-MMP-9 pathway, TREM2-ApoE signaling, insulin receptor trafficking, reelin-related synaptic effects, endoplasmic reticulum stress, and autophagy currently rely primarily on AD research or preclinical evidence. Two recently proposed specific hypotheses-the brain-heart-kidney axis hypothesis and the microglial lipid droplet model-offer valuable conceptual frameworks but should be viewed as testable theories rather than established mechanisms. To date, no ApoE4-targeted therapies have been proven effective for CSVD-related cognitive impairment future research should prioritize genotype-stratified longitudinal CSVD cohorts, standardized imaging studies, adjustment for Alzheimer's disease (AD) biomarkers, analysis of interactions between vascular risk factors, studies on human white matter tissue, and the development of ApoE4 disease models that integrate chronic hypoperfusion and vascular comorbidities.
SN - 1662-5161
ER -